Rita Vanbever

List of Publications by Year
in descending order

44 papers	2,488 citations	257450 24 h-index	233421 45 g-index
46 all docs	46 docs citations	46 times ranked	2602 citing authors

#	Article	IF	Citations
1	Needle-free iontophoresis-driven Î²-adrenergic sweat rate test. Journal of Cystic Fibrosis, 2022, 21, 407-415.	0.7	3
2	Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy. International Journal of Pharmaceutics, 2022, 612, 121355.	5.2	3
3	PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages. International Journal of Pharmaceutics, 2021, 593, 120107.	5.2	7
4	Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice. Journal of Controlled Release, 2021, 329, 1054-1065.	9.9	14
5	PEGylation of Recombinant Human Deoxyribonuclease I Provides a Longâ€Acting Version of the Mucolytic for Patients with Cystic Fibrosis. Advanced Therapeutics, 2021, 4, 2000146.	3.2	7
6	Encapsulation of a CpG oligonucleotide in cationic liposomes enhances its local antitumor activity following pulmonary delivery in a murine model of metastatic lung cancer. International Journal of Pharmaceutics, 2021, 600, 120504.	5.2	19
7	Protein Engineering Strategies for Improved Pharmacokinetics. Advanced Functional Materials, 2021, 31, 2101633.	14.9	28
8	Preclinical evaluation of topically-administered PEGylated Fabâ€™ lung toxicity. International Journal of Pharmaceutics: X, 2019, 1, 100019.	1.6	2
9	Activity of Antibiotics against Staphylococcus aureus in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	20
10	Cationic Nanoliposomes Are Efficiently Taken up by Alveolar Macrophages but Have Little Access to Dendritic Cells and Interstitial Macrophages in the Normal and CpG-Stimulated Lungs. Molecular Pharmaceutics, 2019, 16, 2048-2059.	4.6	9
11	Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation. Journal of Controlled Release, 2018, 272, 62-71.	9.9	38
12	Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum. Clinical Science, 2018, 132, 1439-1452.	4.3	13
13	PEGylation prolongs the pulmonary retention of an anti-IL-17A Fabâ€™ antibody fragment after pulmonary delivery in three different species. International Journal of Pharmaceutics, 2017, 521, 120-129.	5.2	25
14	SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study. Pharmaceutical Research, 2017, 34, 290-300.	3.5	59
15	Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy. International Journal of Pharmaceutics, 2017, 524, 159-167.	5.2	18
16	PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma. Journal of Controlled Release, 2016, 239, 62-71.	9.9	62
17	Synthesis and In Vitro Evaluation of Polyethylene Glycol-Paclitaxel Conjugates for Lung Cancer Therapy. Pharmaceutical Research, 2016, 33, 1671-1681.	3.5	16
18	Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation. International Journal of Pharmaceutics, 2015, 495, 981-990.	5.2	24

#	Article	IF	Citations
19	Delivery strategies for sustained drug release in the lungs. Advanced Drug Delivery Reviews, 2014, 75, 81-91.	13.7	298
20	PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. Journal of Controlled Release, 2014, 187, 91-100.	9.9	72
21	Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 40-48.	4.3	28
22	Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments. International Journal of Pharmaceutics, 2013, 454, 107-115.	5.2	15
23	Mucosal and Systemic Immune Responses to Mycobacterium tuberculosis Antigen 85A following Its Co-Delivery with CpG, MPLA or LTB to the Lungs in Mice. PLoS ONE, 2013, 8, e63344.	2.5	34
24	Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages. Biochemical and Biophysical Research Communications, 2012, 420, 857-861.	2.1	47
25	Fate of nanomedicines in the lungs. Current Opinion in Colloid and Interface Science, 2011, 16, 246-254.	7.4	103
26	Nicotinamide enhances apoptosis of G(M)-CSF-treated neutrophils and attenuates endotoxin-induced airway inflammation in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 300, L354-L361.	2.9	14
27	Analysis of sialoadhesin expression on mouse alveolar macrophages. Immunology Letters, 2009, 124, 77-80.	2.5	20
28	PEGylation of Anti-Sialoadhesin Monoclonal Antibodies Enhances Their Inhibitory Potencies without Impairing Endocytosis in Mouse Peritoneal Macrophages. Bioconjugate Chemistry, 2009, 20, 295-303.	3.6	9
29	Preclinical models for pulmonary drug delivery. Expert Opinion on Drug Delivery, 2009, 6, 1231-1245.	5.0	101
30	Safety evaluation of pulmonary influenza vaccination in healthy and â€œasthmaticâ€•mice. Vaccine, 2008, 26, 2360-2368.	3.8	8
31	Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 839-844.	4.3	62
32	The Inhibitory Potencies of Monoclonal Antibodies to the Macrophage Adhesion Molecule Sialoadhesin Are Greatly Increased Following PEGylation. Bioconjugate Chemistry, 2008, 19, 2088-2094.	3.6	5
33	The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response. Immunology, 2007, 122, 316-325.	4.4	67
34	Performance-driven, pulmonary delivery of systemically acting drugs. Drug Discovery Today: Technologies, 2005, 2, 39-46.	4.0	10
35	Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L1002-L1008.	2.9	91
36	Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. Journal of Controlled Release, 2004, 96, 233-244.	9.9	129

#	Article	IF	Citations
37	Aerosolization properties, surface composition and physical state of spray-dried protein powders. Journal of Controlled Release, 2004, 99, 357-367.	9.9	111
38	Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1â€“34) from rat lungs. Journal of Pharmaceutical Sciences, 2004, 93, 1241-1252.	3.3	75
39	Confocal imaging of rat lungs following intratracheal delivery of dry powders or solutions of fluorescent probes. Journal of Controlled Release, 2002, 83, 331-341.	9.9	40
40	Comparison of particle sizing techniques in the case of inhalation dry powders. Journal of Pharmaceutical Sciences, 2001, 90, 2032-2041.	3.3	55
41	Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. Journal of Controlled Release, 2001, 70, 329-339.	9.9	266
42	Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharmaceutical Research, 1999, 16, 555-561.	3.5	96
43	Formulation and physical characterization of large porous particles for inhalation. Pharmaceutical Research, 1999, 16, 1735-1742.	3.5	285
44	Sustained release of insulin from insoluble inhaled particles. Drug Development Research, 1999, 48, 178-185.	2.9	46